Pfizer Boosts Cost-Savings Target to $6.7B, Sets 2028 Berobenatide Approval Goal
PFE is trading near its 52-week low of $23.4 (6.3% above the low) on light trading volume (0.3× avg).
Summary
Pfizer raised its net cost-savings target to $6.7 billion through 2029, adding $1 billion from its cost realignment program on top of the $2.5 billion announced in the Q2 10-Q. The company also laid out pipeline milestones: a pivotal trial for Nurtec in chronic migraine starts this year, and it targets first approval for obesity drug berobenatide in 2028, with a 10-study Phase 3 program advancing this year. Long-term, Pfizer aims for high single-digit revenue CAGR from 2028 to 2033 and expects a post-2028 cash flow boost from a Vyndamax patent settlement. The cost-savings increase signals aggressive margin defense, while the berobenatide timeline gives concrete shape to the obesity pipeline that has been a key investor focus. The stock has been under pressure, down 33% over the past decade, and this update provides a clearer path to recovery. Watch for the berobenatide Phase 3 initiation details and the chronic migraine trial start later this year.
At the time of this announcement, PFE was trading at $24.89 on NYSE in the Life Sciences sector, with a market capitalization of approximately $141.8B. The 52-week trading range was $23.40 to $28.75. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.